Prostate cancer is the most common cancer among those assigned male at birth, with one in eight diagnosed during their lifetime. But with five-year survival rates of 90%, it’s also one of the most successful cancers to treat, making survivorship care even more important.
Providing variety of methods and approaches allows healthcare workers to choose the best options for them to mitigate and treat psychological distress from the COVID-19 coronavirus pandemic, researchers said in a preliminary report published in the Joint Commission Journal on Quality and Patient Safety.
On May 28, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to infigratinib (Truseltiq™), a kinase inhibitor for patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or other rearrangement as detected by an FDA-approved test. FDA also approved the FoundationOne® CDx as a companion diagnostic for infigratinib.
Effectively treating a cancer diagnosis requires an immense amount of collaboration. Clinicians are equipped with the clinical knowledge to provide the best care possible, and sharing that crucial information with each other and patients is essential for optimal patient outcomes.
On May 28, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sotorasib (Lumakras™), a RAS GTPase family inhibitor, for adult patients with KRAS G12Cmutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.
On May 27, 2021, the U.S. Food and Drug Administration (FDA) approved piflufolastat F 18 (Pylarify®), a drug for positron-emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in patients with prostate cancer.
Oncology nursing is an immensely rewarding calling, but the emotional burdens and stressors can feel overwhelming. Office politics, career changes, and providing end-of-life care are difficult to navigate alone, but partnering with mentors helps nurses work through challenges and grow as leaders. As I look back on my career accomplishments, I can’t deny the influence from several mentors sprinkled throughout that trajectory. Each one gifted me with the insight to develop specific skills that enhanced my practice.
ONS released ONS On-Demand™, a new distribution platform that provides an efficient solution to deliver ONS evidence-based education to institutions and healthcare networks. The tool gives administrators the ability to assign courses to staff and offers reporting on course completion activity. The product supports nursing continuing professional development reporting requirements for accreditation programs and staff continuous professional development.
Using positron-emission tomography with a radioactive tracer identifies levels of progesterone receptor in patients with estrogen receptor-positive breast cancer, researchers reported in Nature Communications. The diagnostic tool would help clinicians determine which patients are most likely to respond to hormone therapies for breast cancer.
Clinicians are already seeing an increase in late-stage cancer diagnoses that they attribute to the pandemic-driven pause in cancer screening and treatment adherence, according to the results of a survey from the American Society for Radiation Oncology.